Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-09-18
2007-09-18
Foley, Shanon (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S387100, C424S130100, C424S135100, C424S141100
Reexamination Certificate
active
11056825
ABSTRACT:
This invention generally relates to methods of producing an antibody phage population having affinity for a tumor cell target expressing a metastatic phenotype. The invention further relates to antibody compositions that specifically bind to a cell surface receptor on the metastatic cell.
REFERENCES:
patent: 5502167 (1996-03-01), Waldmann et al.
patent: 5578704 (1996-11-01), Kim et al.
patent: 5590079 (1996-12-01), Lee et al.
patent: 5652109 (1997-07-01), Kim et al.
patent: 5652110 (1997-07-01), Kim et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 6171588 (2001-01-01), Carron et al.
patent: 6193968 (2001-02-01), Carron et al.
patent: 6359126 (2002-03-01), Kim et al.
patent: 6369204 (2002-04-01), Kim et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6531580 (2003-03-01), Huse et al.
patent: 6596850 (2003-07-01), Huse
patent: 2002/0025510 (2002-02-01), Strongin et al.
patent: 2003/0129188 (2003-07-01), Barbas et al.
patent: 2003/0166872 (2003-09-01), Huse et al.
patent: 2004/0001835 (2004-01-01), Woessner et al.
patent: 2004/0005550 (2004-01-01), Shattil et al.
Zheng et al., cancer research, vol. 59, p. 1655-1664, 1999.
Lanza et al., Blood Cells, Molecules and Disease, vol. 23, p. 230-241, 1997.
Tatiana et al., Experimental Cell Research vol. 254, p. 299-308, 2000.
Felding-Habermann et al., Clinical & Experimental Metastasis, vol. 19, p. 427-436, 2002.
Yun et al., Cancer Research, vol. 56, p. 3103-3111, 1996.
Byzova et al., Experimental Cell Research vol. 254, p. 299-308, 2000.
McNeel et al., “Phase I Trial of a Monoclonal Antibody Specific for ανβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect of Tumor Perfusion,”Clin. Cancer Res.,2005, 11(21), 7851-7860.
Vacca et al., “ανβ3 Integrin Engagement Modulates Cell Adhesion, Proliferation, and Protease Secretion in Human Lymphoid Tumor Cells,”Exp. Hematol.,2001, 29(8), 993-1003.
Al Hajj,Proc. Natl. Acad. Sci. U.S.A,“Prospective identification of tumorigenic breast cancer cells,” 100: 3983-3988, 2003.
Ali, “Medicial Management of Bone Metastases,”Clin. Orthop.,S132-S137, 2003.
Amirkhosravi et al., “Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral Gpllb/IIIa antagonist XV454,”Thromb. Haemost.,90: 549-554, 2003.
Asano et al., “Masking of Phosphatidylserine Inhibits Apoptotic Cell Engulfment and Induces Autoantibody Production In Mice,”J Exp Med,200:459-467, 2004.
Bakewell et al., “Platelet and osteoclast B3integrins are critical for bone metastasis,”Proc. Natl. Acad. Sci. U.S.A,100: 14205-14210, 2003.
Beglova et al., “Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation,”Nat. Struct. Biol.9: 282-287, 2002.
Biggerstaff et al., “Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis,”Clin.Exp.Metastasis,17: 723-730, 1999.
Bogenrieder et al., “Axis of evil: molecular mechanisms of cancer metastasis,”Oncogene22: 6524-6536, 2003.
Bougie et al., “Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied CPIIb/IIIa,”Blood,100:2071-2076, 2002.
Brooks et al., “Integrin ανβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels,”Cell,79: 1157-1164, 1994.
Brooks et al., “Requirement of Vascular Integrin ανβ3for Angiogenesis,”Science,264: 569-571, 1994.
Buckley et al., “RGD peptides induce apoptosis by direct caspase-3 activation,”Nature397: 534-539, 1999.
Calzada et al., “Agonist-specific Structural Rearrangements of Integrin αIIbβ3,”J. Biol. Chem.277: 39899-39908, 2002.
Chen et al., “MicroPET and Autoradiographic Imaging of Breast Cancer αν-Integrin Expression Using18F- and64Cu-Labeled RGD Peptide,”Bioconjug. Chem.,15: 41-49, 2004.
Chu and Ng, “Interaction of West Nile Virus with ανβ3Integrin Mediates Virus Entry into Cells,”Journal of Biol. Chem.,279:54533-54541, 2004.
Chung et al., “Integrin αIIbβ3-specific synthetic human monoclonal antibodies and HCDR3 peptides that potently inhibit platelet aggregation,”FASEB Journal,18:361-363, 2004.
Coelho et al., “RGD- and MLD-disintegrins, jarastatin and EC3, activated integrin-mediated signaling modulating the human neutrophils chemotaxis, apoptosis and IL-8 gene expression,”Experimental Cell Research,292:371-384, 2004.
Collins et al., “Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression,”J. Cell Sci.,114: 3865-3872, 2001.
Ding et al., “Promotion of Malignant Astrocytoma Cell Migration by Osteopontin Expressed in the Normal Brain: Differences in Itegrin Signaling during Cell Adhesion to Osteopontin Versus Vitronectin,”Cancer Res.,62: 5336-5343, 2002.
Evans et al., “A tumor-associated β1 integrin mutation that abrogates epithelial differentiation control,”J. Cell Biol.,160: 589-596, 2003.
Felding-Habermann et al., “Role of β3Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow,”J. Biol. Chem.271: 5892-5900, 1996.
Felding-Habermann, B., et al., “Involvement of tumor integrin ανβ3in hematogenous metastasis of human melanoma cells,”Clin. Exp. Metastasis19: 427-436, 2002.
Felding-Habermann, “Integrin adhesion receptors in tumor metastasis,”Clin. Exp. Metastasis20: 203-213, 2003.
Felding-Habermann, et al., “Integrin activation controls metastasis in human breast cancer,”Proc. Natl. Acad. Sci. U. S. A98: 1853-1858, 2001.
Frenkel et al., “Filamentous phage as vector-mediated antobidy delivery to the brain,”Proc. Natl. Acad. Sci. U.S.A, 99:5675-5679, 2002.
Furger, K. A., et al., “β3Integrin Expression Increases Breast Carcinoma Cell Responsiveness to the Malignancy-Enhancing Effects of Osteopontin,”Mol. Cancer Res.,1: 810-819, 2003.
Gao, C., et al., “De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods,”J. Immunol. Methods274: 185-197, 2003.
Garnett, M. C., “Targeted drug conjugates: principles and progress,”Adv. Drug Deliv. Rev., 53: 171-216, 2001.
Gladson et al., “Stage-Specific Expression of Integrin ανβ3in Neuroblastic Tumors,”Am. J. Pathol., 148: 1423-1434, 1996.
Gladson et al., “Extracellular Matrix of Gliomas: Modulation of Cell Function,”J. Neuropathol. Exp. Neurol., 58: 1029-1040, 1999.
Gline et al., “A 50-Å Separation of the Integrin ανβ3Extracellular Domain C Termini Reveals an Intermediate Activation State,”J Biol Chem, 279:54567-54572, 2004.
Goldenberg, D. M., “Advancing role of radiolabeled antibodies in the therapy of cancer,”Cancer Immunol. Immunother., 52: 281-296, 2003.
Gui et al., “Integrin expression in primary breast cancer and its relation to axillary nodal status,”Surgery, 117: 102-108, 1995.
Hood et al., “Role of Integrins in Cell Invasion and Migration,”Nat. Rev. Cancer2: 91-100, 2002.
Hughes et al., “Breaking the Integrin Hinge,”J. Biol. Chem.271: 6571-6574, 1996.
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,”Science,246:1275-1281, 1989.
Karadag et al., “Bone Sialoprotein, Matrix Metalloproteinase 2, and ανβ3Integrin in Osteotropic Cancer Cell Division,”J Natl. Cancer Inst., 96:956-965, 2004.
Kiosses et al., “Rac recruits high-affinity integrin ανβ3to lamellipodia in endothelial cell migration,”Nat. Ce
Felding-Habermann Brunhilde
Janda Kim D.
Saven Alan
Foley Shanon
The Scripps Research Institute
Yao Lei
LandOfFree
Methods and compositions for inhibition of metastasis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of metastasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of metastasis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731998